{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:26:53Z","timestamp":1790879213809,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T00:00:00Z","timestamp":1301875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Chair's Grant","award":["U10 CA98543-08"],"award-info":[{"award-number":["U10 CA98543-08"]}]},{"name":"National Cancer Institute, National Institutes of Health, Bethesda, MD, USA","award":["U10 CA98413-08"],"award-info":[{"award-number":["U10 CA98413-08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an open label, multi\u2010center phase II clinical trial. Courses were defined as consecutive 28\u2010day intervals. Oral imatinib was administered daily at 340\u2009mg\/m<jats:sup>2<\/jats:sup> without interruption in the absence of toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010one children received 978 28\u2010day courses of imatinib. The most common toxicities encountered were hematologic. Forty\u2010one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (&gt;3 log reduction) was 27%. Progression\u2010free and overall survival at 3 years were 72%\u2009\u00b1\u20096.4% and 92%\u2009\u00b1\u20093.9%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Daily oral imatinib at a dose of 340\u2009mg\/m<jats:sup>2<\/jats:sup> is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.). Pediatr Blood Cancer 2011;57:56\u201362. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.23031","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T17:14:30Z","timestamp":1301937270000},"page":"56-62","source":"Crossref","is-referenced-by-count":56,"title":["Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group"],"prefix":"10.1002","volume":"57","author":[{"given":"Martin A.","family":"Champagne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia H.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D.","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Arceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin O.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,4]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"SmithMA Gloeckler RiesLA GurneyJG et al. Leukemia in Cancer incidence and survival among children and adolescents: United States SEER program 1975\u20101995 National Cancer Institute SEER program. Ries LAG Smith MA Gurney JG Linet M Tamra T Young JL Bunin GR (eds).1999; 99\u20104649:17\u201334."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3637"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00629-5"},{"key":"e_1_2_6_5_2","first-page":"80","article-title":"Unrelated\u2010donor bone marrow transplantation for Philadelphia chromosome\u2010positive chronic myelogenous leukemia in children: Experience of eight European Countries. The EBMT Paediatric Diseases Working Party","volume":"18","author":"Dini G","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.834"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013339"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0025"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3800"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3869"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq201"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404716"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051140"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24066"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.41769"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1309\/NR81-VCU0-CKW1-4HT9"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1309\/A4RGP4LF12GGH8MW","article-title":"Chronic myeloid leukemia following therapy with imatinib mesylate","volume":"113","author":"Frater JL","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404051"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2003.50038"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/73542"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10306"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20062"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068073"},{"key":"e_1_2_6_35_2","first-page":"52a","article-title":"Beneficial effects of cytogenetic and molecular response on long\u2010term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib: Update from the IRIS study","volume":"106","author":"Simonsson B","year":"2006","journal-title":"Blood"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031682"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23031","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:30:57Z","timestamp":1700487057000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7,15]]}},"alternative-id":["10.1002\/pbc.23031"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23031","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,4]]}}}